Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 1, 2012, Pages 64-71

  Prosperini, Luca ^a   Giannì, Costanza ^a   Leonardi, Laura ^a   De Giglio, Laura ^b   Borriello, Giovanna ^a   Galgani, Simonetta ^c   Pozzilli, Carlo ^a   Gasperini, Claudio ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

breakthrough disease; glatiramer acetate; interferon beta; multiple sclerosis; natalizumab; observational study; therapeutic algorithm

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM PENTETATE; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; ARTICLE; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; ITALY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RELAPSE;

EID: 84855925874     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511417481     Document Type: Article

References (38)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFN Beta Multiple Sclerosis Study Group. Neurology. 1993 ; 43: 655-661
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996 ; 39: 285-294 (Pubitemid 26100751)
3. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998 ; 352: 1498-1504
4. Johnson KP, Brooks BR, Cohen JA, et al. The Copolymer-1 Multiple Sclerosis Study Group. Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995 ; 45: 1268-1276
5. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009 ; 8: 545-559
6. Karussis D, Biermann LD, Bohlega S, et al. International Working Group for Treatment Optimization in MS. A recommended treatment algorithm in relapsing MS: report of an international consensus meeting. Eur J Neurol. 2006 ; 13: 61-71
7. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008 ; 255: 1449-1463
8. Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol. 2005 ; 62: 785-792 (Pubitemid 40656095)
9. Durelli L, Barbero P, Bergui M, et al. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders. J Neurol. 2008 ; 255: 1315-1323
10. Zwibel HL. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurol Scand. 2006 ; 113: 378-386 (Pubitemid 44046323)
11. Caon C, Din M, Ching W, et al. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. 2006 ; 13: 471-474 (Pubitemid 43823361)
12. Limmroth V, Rolf M, Zettl UK, et al. Quality assessment in multiple sclerosis quality (QUASIMS): a comparison of different therapies for relapsing-remitting multiple sclerosis. J Neurol. 2007 ; 254: 67-77 (Pubitemid 46295070)
13. Carrá A, Onaha P, Luetic G, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol. 2008 ; 15: 386-393 (Pubitemid 351422381)
14. Gajofatto A, Bacchetti P, Grimes B, et al. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler. 2009 ; 15: 50-58
15. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
16. Hartung HP, Gonsette R, König N, et al. Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002 ; 360: 2018-2025
17. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines form the International Panel on the diagnosis of Multiple Sclerosis. Ann Neurol. 2001 ; 50: 121-127
18. Kurtzke JF. Rating neurological impairment in Multiple Sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452 (Pubitemid 14237132)
19. European Medicines Agency (EMA). Available at: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Summary-for-the-public/human/000603/ WC500044688.pdf (last updated: 13 12 2010).
20. Filippi M, Rocca MA, Arnold DL, et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol. 2006 ; 13: 313-325
21. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology. 2010 ; 74 (Suppl. 3). S3 - S7
22. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004 ; 23: 2937-2960 (Pubitemid 39200133)
23. Trojano M, Pellegrini F, Paolicelli D, et al. Observational studies: propensity score analysis of non-randomized data. Int MS J. 2009 ; 16: 90-97
24. Greenland S. Basic methods for sensitivity analysis of biases. Int J Epidemiol. 1996 ; 25: 1107-1116 (Pubitemid 27013514)
25. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009 ; 256: 405-415
26. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 ; 8: 254-260
27. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007 ; 69: 1391-1403 (Pubitemid 47511460)
28. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. N Engl J Med. 2006 ; 354: 911-923
29. Freedman MS, Hughes B, Mikol DD, et al. Efficacy of disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic comparison. Eur Neurol. 2008 ; 60: 1-11 (Pubitemid 351799060)
30. Castillo-Trivino T, Mowry EM, Gajofatto A, et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011 ; 3: e16664
31. Klawiter EC, Cross AH, Naismith RT. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?. Neurology. 2009 ; 22; 73: 984-990
32. Trojano M, Pellegrini F, Paolicelli D, et al. Italian Multiple Sclerosis Database Network (MSDN) Group. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol. 2009 ; 66: 513-520
33. Healy BC, Glanz BI, Stankiewicz J, et al. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler. 2010 ; 16: 1483-1489
34. Sorensen PS, Deisenhammer F, Duda P, et al. EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis: Guidelines on use of anti-IFN beta antibody measurements in multiple sclerosis: report of an EFNS. Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol. 2005 ; 12: 817-827 (Pubitemid 41597593)
35. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002 ; 359: 1453-1460 (Pubitemid 34457761)
36. Panitch H, Goodin DS, Francis G, et al. EVIDENCE Study Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology. 2002 ; 59: 1496-1506 (Pubitemid 35387053)
37. Prosperini L, Borriello G, De Giglio L, et al. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?. BMC Neurol. 2011 ; 11: 26
38. Trojano M. Is it time to recognize the use of observational data to estimate treatment effectiveness in multiple sclerosis?. Neurology. 2007 ; 69: 1478-1479 (Pubitemid 47537853)